DelveInsight’s, “CAR T Cell Therapy Competitive Landscape 2023” report provides comprehensive insights about 250+ CAR-T Cell Therapy companies and 500+ drugs in CAR T – Cell Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the CAR-T Cell Therapy Report

• DelveInsight’s CAR-T Cell Therapy report depicts a robust space with 250+ active players working to develop 500+ pipeline therapies for CAR-T Cell Therapy treatment.
• The leading companies working in the CAR-T Cell Therapy Market include Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, JW Therapeutics, Gilead Sciences, Cellular Biomedicine Group, Gracell Bio, Mustang Bio, Servier, iCell Gene Therapeutics, Kecellitics Biotech Company Ltd, Gilead sciences, Miltenyi Biotech, Nanjing KAEDI Biotech, Liminatus Pharma, Yake Biotechnology, AffyImmune Therapeutics, Fundamenta Therapeutics, Actinium Pharmaceuticals, Allogene Therapeutics, Celyad Oncology, Maxcyte, Sorrento Therapeutics, Cellular Biomedicine Group, Sorrento Therapeutics, Shanghai GeneChem Co., Ltd., Sensei Biotherapeutics, Obsidian Therapeutics, Beijing Biohealthcare Biotechnology Co. Ltd. , Eutilex/Utilities, Precigen, Inc., Miltenyi Biomedicine, Wugen, WindMIL Therapeutics, MiNK Therapeutics, CiMaas, Catamaran Bio, Innate Pharma, Healios, Chimeric Therapeutics, ONK Therapeutics, Neukio Biotherapeutics, Exacis Biotherapeutics, Editas Medicine, and others.
• Promising CAR-T Cell Therapy Therapies in the various stages of development include Relmacabtagene autoleucel, KTE-X19, Abecma, Zevorcabtagene autoleucel, Descartes 011, AUTO8, SG299, and others.
• December 2023: Peter MacCallum Cancer Centre, Australia announced a study of phase 1 clinical trials for JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent. This clinical trial will investigate the in vivo trafficking of cilta-cel in extramedullary myeloma using 64Cu Super Paramagnetic Iron Oxide Nanoparticle (64Cu SPION) and Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI).
• December 2023: University of Pennsylvania announced a study of Phase 2 clinical trials for Cevostamab. This is a Phase 2, open-label, single-arm, single stage, single-institution study, with an initial safety run-in period. Potential participants with relapsed/refractory myeloma who are undergoing standard of care, commercially-available BCMA-directed CAR T cell therapy may be identified pre-CAR T cell infusion but are not consented and enrolled until at least 4-6 weeks after CAR T cell infusion, once recovered from acute toxicities.

 

Request a sample and discover the recent advances in CAR-T Cell Therapy Drugs @ CAR-T Cell Therapy Competitive Landscape Report

 

The CAR-T Cell Therapy report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing, and acquisition – deal values trends. The sub-segmentation is described in the CAR-T Cell Therapy report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.

 

CAR-T Cell Therapy Overview

CAR T-cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. A CAR combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signaling domains of the TCR chain and additional costimulatory domains from receptors, such as CD28, OX40, and CD137.

 

Find out more about CAR-T Cell Therapy Analytical Perspective: In-depth Commercial Assessment @ CAR-T Cell Therapy Collaboration Analysis by Companies

 

CAR-T Cell Therapy Companies and Therapies

• CARsgen: Zevorcabtagene autoleucel
• Cartesian Therapeutics: Descartes 011
• Autolus Therapeutics PLC: AUTO8
• Sana Biotechnology: SG299

 

CAR T- Cell Therapy Competitive Landscape

The CAR-T Cell Therapy competitive landscape report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

 

CAR T- Cell Therapy Report Assessment

• CAR T-Cell Therapy Company Analysis
• CAR T-Cell Therapy Therapeutic Assessment
• CAR T- Cell Therapy Pipeline Assessment
• CAR T-Cell Therapy Inactive Drugs Assessment
• CAR T-Cell Therapy Unmet Needs

 

Learn more about the emerging CAR-T Cell Therapy Competitive Landscape @ CAR-T Cell Therapy Market Drivers and Barriers, Unmet Needs

 

Scope of the CAR-T Cell Therapy Report

• Coverage- Global
• CAR-T Cell Therapy Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
• CAR-T Cell Therapy Companies- Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, JW Therapeutics, Gilead Sciences, Cellular Biomedicine Group, Gracell Bio, Mustang Bio, Servier, iCell Gene Therapeutics, Kecellitics Biotech Company Ltd, Gilead sciences, Miltenyi Biotech, Nanjing KAEDI Biotech, Liminatus Pharma, Yake Biotechnology, AffyImmune Therapeutics, Fundamenta Therapeutics, Actinium Pharmaceuticals, Allogene Therapeutics, Celyad Oncology, Maxcyte, Sorrento Therapeutics, Cellular Biomedicine Group, Sorrento Therapeutics, Shanghai GeneChem Co., Ltd., Sensei Biotherapeutics, Obsidian Therapeutics, Beijing Biohealthcare Biotechnology Co. Ltd. , Eutilex/Utilities, Precigen, Inc., Miltenyi Biomedicine, Wugen, WindMIL Therapeutics, MiNK Therapeutics, CiMaas, Catamaran Bio, Innate Pharma, Healios, Chimeric Therapeutics, ONK Therapeutics, Neukio Biotherapeutics, Exacis Biotherapeutics, Editas Medicine, and others.
• CAR-T Cell Therapy Therapies- Relmacabtagene autoleucel, KTE-X19, Abecma, Zevorcabtagene autoleucel, Descartes 011, AUTO8, SG299, and others.

 

Dive deep into rich insights for new drugs for CAR-T Cell Therapy Product Developmental Activities, Visit @ CAR-T Cell Therapy Research and Development Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. CAR T – Cell Therapy: Overview
4. CAR T – Cell Therapy-Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. CAR T – Cell Therapy: Company and Product Profiles (Marketed Therapies)
8. JW Therapeutics
9. Relmacabtagene autoleucel
10. Oncolytic Virus Cancer Therapy: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Registered)
12. CARsgen
13. Zevorcabtagene autoleucel
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Cartesian Therapeutics
17. Descartes 011
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. Autolus Therapeutics
21. AUTO-8
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Sana Biotechnology
25. SG299
26. Drug profiles in the detailed report…..
27. Inactive Products
28. CAR T – Cell Therapy – Unmet needs
29. CAR T – Cell Therapy– Market drivers and barriers
30. Appendix

 

For further information on the CAR-T Cell Therapy Report @ CAR-T Cell Therapy Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market